Liralin-DP Tablets: A Combined Approach to Blood Sugar Control

Liralin-DP Tablets combine the precise action of Dapagliflozin (10mg) and Linagliptin (5mg) to provide a comprehensive treatment for Type 2 diabetes. This unique formulation aids in glucose control by effectively lowering blood sugar levels.

Dapagliflozin: This SGLT2 inhibitor helps lower blood glucose by blocking the reabsorption of glucose in the kidneys, thus promoting its excretion through urine.
Linagliptin: This DPP-4 inhibitor controls postprandial hyperglycemia by inhibiting the action of dipeptidyl peptidase-4, which normally breaks down incretins like GLP-1 and GIP.

Liralin-DP Tablets are formulated for convenient administration, making them a valuable option for individuals managing their blood sugar effectively. This combination therapy is designed for patients who require additional assistance in managing blood glucose levels alongside lifestyle modifications.

Please note: This information is intended for general knowledge and does not replace professional medical advice. Consult with your healthcare provider before taking any medication, including Liralin-DP Tablets.